Repeated Rhenium-188-HEDP versus Radium-223-chloride in patients with metastatic castration-resistant prostate cancer: the RARE study. - RaRe

Vrije Universiteit Medisch Centrum0 个研究点目标入组 402 人开始时间: 待定最近更新: 2024年2月28日

研究概览

暂无简介。

•- male, 18 years and older
•- histologically confirmed prostate cancer
•- bone metastases (*6 lesions) with pathological uptake at bone scintigraphy
•- WHO performance status *2
•- life expectancy at least 6 months
•- castration resistant disease (testosterone level *1.7nmol/L)
•- Progression on or after two previous treatments (other than LHRH analogues) including docetaxel), or inability to receive other treatments.
•- baseline PSA * 5 ng/ml with evidence of progressively increasing PSA
•- symptomatic disease with either regular use of analgesic medication or treatment with external beam radiotherapy within the previous 12 weeks
•- adequate renal and hematologic function
•- written informed consent

•- treatment with chemotherapy within the previous 4 weeks
•- treatment with abiraterone and enzalutamide within the previous 5 days
•- Previous hemibody external radiotherapy
•- systemic radiotherapy with radioisotopes within the previous 24 weeks
•- malignant lymhpadenopathy * 3cm in short axis diameter
•- presence of visceral metastases
•- imminent of established spinal cord compression
•- active uncontrolled infections
•- history of another malignancy within the last 5 years except adequatly treated basal cell carcinoma of the skin
•- any serious uncontrolled concomitant disease

发起方